InnoCan Pharma (InnoCan Pharma) Cash-to-Debt : 117.73 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is InnoCan Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. InnoCan Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 117.73.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, InnoCan Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for InnoCan Pharma's Cash-to-Debt or its related term are showing as below:

INNPF' s Cash-to-Debt Range Over the Past 10 Years
Min: 27.35 Med: 130.95 Max: 14141
Current: 115.82

During the past 6 years, InnoCan Pharma's highest Cash to Debt Ratio was 14141.00. The lowest was 27.35. And the median was 130.95.

INNPF's Cash-to-Debt is ranked better than
88.62% of 1046 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs INNPF: 115.82

InnoCan Pharma Cash-to-Debt Historical Data

The historical data trend for InnoCan Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

InnoCan Pharma Cash-to-Debt Chart

InnoCan Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

27.40

61.53

11,048.00

145.50

117.73

InnoCan Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															145.50	157.27	129.73	251.50	117.73

Competitive Comparison of InnoCan Pharma's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCan Pharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Cash-to-Debt falls into.

InnoCan Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

InnoCan Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.885	/	(0.022	+	0.011)
	=	117.73

InnoCan Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.885	/	(0.022	+	0.011)
	=	117.73

InnoCan Pharma (OTCPK:INNPF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

InnoCan Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCan Pharma (InnoCan Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (OTCPK:INNPF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

IP4:Germany INNO:Canada

Address

1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7

Website

https://www.innocanpharma.com

InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.